Prevention & Early Outpatient Treatment Protocol For Covid-19
PREVENTION & TREATMENT PROTOCOLS FOR COVID-19
PREVENTION PROTOCOL
lvermectin
1 Prevention for high risk individuals 0.2 mg/kg per dose (take with or after meals) — one dose today, repeat after 48 hours, then one dose weekly*Post COVID-19 exposure prevention
2 0.2 mg/kg per dose (take with or after meals) — one dose today, repeat after 48 hours *Vitamin D31,000–3,000 IU/day Vitamin C500–1,000 mg twice a day Quercetin 250 mg/dayZinc
3 0–40 mg/day Melatonin 6 mg before bedtime (causes drowsiness)
EARLY OUTPATIENT PROTOCOL
lvermectin
10.2–0.4 mg/kg per dose (take with or after meals) — one dose daily, take for 5 days or until recovered *Use upper dose range if: 1) in regions with more aggressive variants; 2) treatment started on or after day 5 of symptoms or in pulmonary phase; or 3) multiple comorbidities/risk factors. Fluvoxamine 50 mg twice daily for 10–14 days. Add to ivermectin if: 1) minimal response after 2 days of ivermectin; 2) in regions with more aggressive variants; 3) treatment started on or after day 5 of symptoms or in pulmonary phase; or 4) numerous comorbidities/risk factors.
Avoid if patient is already on an SSRI. NasopharyngealSteamed essential oil inhalation 3 times a day (i.e. vapo-rub) Sanitationand/or chlorhexidine/benzydamine mouthwash gargles and Betadine nasal spray 2–3 times a day Vitamin D34,000 IU/day Vitamin C500–1,000 mg twice a day Quercetin 250 mg twice a day Zinc100 mg/day Melatonin10 mg before bedtime (causes drowsiness) Aspirin325 mg/day (unless contraindicated) Pulse Oximeter Monitoring of oxygen saturation is recommended (for instructions please see page 2 of this file)
For optional medicines and an overview of the developments in prevention and treatment of COVID-19, please visit www.flccc.net/optional-medicines.
*The dosing may be updated as further scientific studies emerge.
1 The safety of ivermectin in pregnancy has not been established. A discussion of benefits vs. risks with your provider is required prior to use, particularly in the 1st trimester.
2 To use if a household member is COVID-19 positive, or you have prolonged exposure to a COVID-19 positive patient without wearing a mask
3 For late phase — hospitalized patients — see the FLCCC’s MATH+ Hospital Treatment Protocol for COVID-19 on www.flccc.net
IVERMECTIN
Summary of the Clinical Trials Evidence for Ivermectin in COVID-19
Ivermectin, an anti-parasitic medicine whose discovery won the Nobel Prize in 2015, has proven, highly potent, anti-viral and anti-inflammatory properties in laboratory studies. In the past 4 months, numerous, con–trolled clinical trials from multiple centers and countries worldwide are reporting consistent, large improvements in COVID-19 patient outcomes when treated with ivermectin.
Our comprehensive scientific review of these referenced trials on ivermectin can be found on www.flccc.net/flccc-ivermectin-in-the-prophylaxis-and-treatment-of-covid-19/For a quick overview, a One-page Summary of our review on ivermectin can be found on www.flccc.net/one-page-summary-of-the-clini–cal-trials-evidence-for-ivermectin-in-covid-19/
Pulse Oximeter (usage instructions)
In symptomatic patients, monitoring with home pulse oximetry is recommended (due to asymptomatic hypoxia). The limitations of home pulse oximeters should be recognized, and validated de–vices are preferred. Multiple readings should be taken over the course of the day, and a downward trend should be regarded as ominous. Baseline or ambulatory desaturation < 94 percent should prompt hospital admission.
The following guidance is suggested: –Use the index or middle finger; avoid the toes or ear lobe–Only accept values associated with a strong pulse signal–Observe readings for 30–60 seconds to identify the most common value–Remove nail polish from the finger on which measurements are made–Warm cold extremities prior to measurement
A summary of the published data supporting the rationale for Ivermectin use in our I-MASK+ protocol can be downloaded from www.flccc.net/flccc-ivermectin-summaryFor updates, references, and information on the FLCCC Alliance, the I-Mask+ Prevention & Early Outpatient Treatment Protocol for COVID-19 and the MATH+ Hospital Treatment Protocol for COVID-19, please visit our website www.flccc.net
See more here: FLCCC-Alliance
Header image: Kabul Hostel
Please Donate Below To Support Our Ongoing Work To Expose The Lies About COVID19
PRINCIPIA SCIENTIFIC INTERNATIONAL, legally registered in the UK as a company 
incorporated for charitable purposes. Head Office: 27 Old Gloucester Street, London WC1N 3AX.
Trackback from your site.